Yamamoto FJK, López MA, Chávez MCI, Rodríguez VM, Uscanga L, Granados J

Language: Spanish
References: 27
Page: 3-17
PDF size: 70.99 Kb.

ABSTRACT

Background: Prescription for cinitapride includes gastroesophageal reflux, functional dyspepsia and irritable bowel syndrome which have a great medical and social impact. Objective: To evaluate the efficacy and tolerability of cinitapride in the management of these diseases.
Material and methods: Clinical and multicentric study that includes 7,320 adult patients (›20 years old), both genders from the outpatient clinic in private practices with diagnosis of gastroesophageal reflux, functional dyspepsia and irritable bowel syndrome. All patients received cinitapride 1 mg three times a day for four weeks.
Results: Global evaluation of symptoms relieve by patient showed considerable improvement in 72.58% of cases, mild improvement in 26.55%, no improvement in 0.84% and worsening of symptoms in 0.03%. On the other hand, the evaluation by physician showed complete relieve of symptoms in 62.35% of cases, mild relieve in 34.27%, minor relieve in 2.92%, no change in 0.42% and worsening of symptoms in 0.05% of cases. Non severe adverse events occurred in 2.9% of patients; headache (n = 27), diarrhea (n = 20), nausea (n = 11), drowsiness (n = 9), dizziness (n = 9), flatulence (n = 9), abdominal pain (n = 9) and meteorism (n = 4) were the most frequent. Diarrhea was presented only in the gastroesophageal reflux (n = 13) and in the dyspepsia (n = 7) groups.
Conclusion: Cinitapride is effective and well tolerated in the treatment of adult patients with gastroesophageal reflux, functional dyspepsia and irritable bowel syndrome.

REFERENCES

1. Vargas MH, Sienra Monge JJ, Salas J. Respiratory complications of gastroesophageal reflux. Rev Inst Nal Enf Resp Mex 1994;7:53-66.

2. Hsu PI, Lai KH, Lo GH. Risk factors for ulcer development in patients with non-ulcer dyspepsia: a prospective two year follow-up study of 209 patients. Gut 2002;51:15-20.

3. Tucci A, Corinaldesi R, Stanghellini V. Helicobacter pylori infection and gastric function in patients with chronic idiopathic dyspepsia. Gastroenterology 1992;103:768-74.

4. Wasserman MJ, Valdovinos Díaz MA. Utilization of medical resources for patients with irritable bowel syndrome in a tertiary hospital. Rev Gastroenterol Mex 1998;63:6-10.

5. Talley NJ, Zinsmeister AR, Schlek CD, Melton LJ. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology 1992;102:1259-68.

6. Camilleri M, Choi MG. Review article: irritable bowel syndrome. Aliment Pharmacol Ther 1997;11:3-15.

7. Heading RC. Prevalence of gastrointestinal symptoms in the general population: a systematic review. Scand J Gastroenterol 1999;231(Suppl 1):3-8.

8. Donahue PE. Basic considerations in gastroesophageal reflux disease. Surg Clin North Am 1997;77:1017-40.

9. Camilleri M. Management of the irritable bowel syndrome. Gastroenterology 2001;120:652-68.

10. Dent J. Management of reflux disease. Gut 2002;50:67-71.

11. Arnalich F, Martínez Hernández PL, Camacho J. Tratamiento de la dispepsia funcional y del síndrome del intestino irritable. Inf Ter Sist Nac Salud 1998;22:1-8.

12. Alarcón de la Lastra C, La Casa C, Martin MJ, Motilva V. Effects of cinitapride on gastric ulceration and secretion in rats. Inflamm Res 1998;47:131-6.

13. Jia H, Li JZ, Leserman J, Hu Y, Drossman DA. Relationship of abuse history and other risk factors with obesity among female gastrointestinal patients. Dig Dis Sci 2004;49:872-7.

14. Talley NJ, Stanghellii V, Heading RC, Koch KL, Malagelada JR, Tytyat GNJ. Functional gastroduodenal disorders. Gut 1999;45(SuppI):1137-42.

15. Klauser AG, Schindlbeck NE, Muller-Lissner SA. Symptoms in gastro-oesophageal reflux disease. Lancet 1990;335:205-8.

16. Monés J, Espinos JC, Carrió I, Calabuig R, Vilardell F. Vaciado gástrico en esofagitis por reflujo. Efecto de la metoclopramida y la cinitaprida. Med Clin (Barc) 1993;93(9):331-4.

17. Surós A, Adell F, De Novoa V, Castellamau J, Diosdado D, Carrasquer J, Merello J. Cinitapride in the treatment of gastroesophageal reflux. Comparative study with metoclopramide and placebo. Rev Med Univ Navarra 1992;37:18-23.

18. Mora F, Añón R, Luceras V, Moreno-Osset E, Minués M, Benages A. Metoclopramida vs cinitaprida en el tratamiento de la dispepsia funcional. Ann Med Intern (Madrid) 1993;10(7):323-6.

19. Herrerías JM, Garcís Montes MJ. Dispepsia no ulcerosa con estreñimiento funcional primario. Evaluación del tratamiento con cinitaprida asociada o no metilcelulosa. Rev Med Univ Navarra 1993:30-35.

20. Miller LG, Jankovic J. Metoclopramide-induced movement’s disorders. Clinical findings with a review of the literature. Arch Intern Med 1989;149:2486-92.

21. Rotmensch HH, Mould GP, Sutton JA, Kilminster S, Moller C, Pero RW. Comparative central nervous system effects and pharmacokinetics of neu-metoclopramide and metoclopramide in healthy volunteers. J Clin Pharmacol 1997;37(3):222.

22. Inkpen T. Metoclopramide-induced extrapyramidal syndromes. J Palliat Care 1993;9:33-34.

23. Samie MR, Dannenhoffer MA, Rozek S. Life-threatening dyskinesia caused by metoclopramide. Mov Disord 1987;2:125-9.

24. Layton D, Key C, Shakir SA. Prolongation of the QT interval and cardiac arrythmias associated with cisapride: limitations of the pharmacoepidemilogical studies and proposals for the future. Pharmacoepidemiol Drug Saf 2003;12:31-40.

25. Wang SH, Lin CY, Huang TY, Wu WS, Chen CC, Tsai SH. QT interval effects of cisapride in the clinical setting. Int J Cardiol 2001;80(2-3):179-83.

26. Smalley W, Shatin D, Wysowski DK, Gurwitz J, Andrade SE, Goodman M, et al. Contraindicated use of cisapride: impact of food and drug administration regulatory action. JAMA 2000;284(23):3036-9.

27. Cubeddu LX. QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs. Am J Ther 2003;10(6):452-7.